|
TEVA Pharmaceutical Industries Limited (TEVA) DCF -Bewertung
IL | Healthcare | Drug Manufacturers - Specialty & Generic | NYSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Teva Pharmaceutical Industries Limited (TEVA) Bundle
Unser DCF -Taschenrechner von Teva Pharmaceutical Industries Limited (TEVA) für die Genauigkeit ermöglicht es Ihnen, die Bewertung von TEVA mit umfassenden Finanzdaten zu bewerten und alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,658.0 | 15,878.0 | 14,925.0 | 15,846.0 | 16,544.0 | 16,539.5 | 16,535.0 | 16,530.5 | 16,526.0 | 16,521.5 |
| Revenue Growth, % | 0 | -4.68 | -6 | 6.17 | 4.4 | -0.02717471 | -0.02717471 | -0.02717471 | -0.02717471 | -0.02717471 |
| EBITDA | -2,094.0 | 4,409.0 | -874.0 | 1,570.0 | -303.0 | 576.2 | 576.0 | 575.9 | 575.7 | 575.5 |
| EBITDA, % | -12.57 | 27.77 | -5.86 | 9.91 | -1.83 | 3.48 | 3.48 | 3.48 | 3.48 | 3.48 |
| Depreciation | 1,557.0 | 1,330.0 | 1,308.0 | 1,153.0 | .0 | 1,116.9 | 1,116.6 | 1,116.3 | 1,115.9 | 1,115.6 |
| Depreciation, % | 9.35 | 8.38 | 8.76 | 7.28 | 0 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 |
| EBIT | -3,651.0 | 3,079.0 | -2,182.0 | 417.0 | -303.0 | -540.7 | -540.5 | -540.4 | -540.3 | -540.1 |
| EBIT, % | -21.92 | 19.39 | -14.62 | 2.63 | -1.83 | -3.27 | -3.27 | -3.27 | -3.27 | -3.27 |
| Total Cash | 2,177.0 | 2,165.0 | 2,801.0 | 3,226.0 | 3,300.0 | 2,837.4 | 2,836.6 | 2,835.9 | 2,835.1 | 2,834.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4,581.0 | 4,529.0 | 3,696.0 | 3,408.0 | 3,059.0 | 3,995.4 | 3,994.4 | 3,993.3 | 3,992.2 | 3,991.1 |
| Account Receivables, % | 27.5 | 28.52 | 24.76 | 21.51 | 18.49 | 24.16 | 24.16 | 24.16 | 24.16 | 24.16 |
| Inventories | 4,403.0 | 3,818.0 | 3,833.0 | 4,021.0 | 3,007.0 | 3,959.9 | 3,958.8 | 3,957.8 | 3,956.7 | 3,955.6 |
| Inventories, % | 26.43 | 24.05 | 25.68 | 25.38 | 18.18 | 23.94 | 23.94 | 23.94 | 23.94 | 23.94 |
| Accounts Payable | 1,756.0 | 1,686.0 | 1,887.0 | 2,602.0 | 2,203.0 | 2,101.8 | 2,101.3 | 2,100.7 | 2,100.1 | 2,099.5 |
| Accounts Payable, % | 10.54 | 10.62 | 12.64 | 16.42 | 13.32 | 12.71 | 12.71 | 12.71 | 12.71 | 12.71 |
| Capital Expenditure | -578.0 | -562.0 | -548.0 | -526.0 | -498.0 | -562.7 | -562.5 | -562.4 | -562.2 | -562.1 |
| Capital Expenditure, % | -3.47 | -3.54 | -3.67 | -3.32 | -3.01 | -3.4 | -3.4 | -3.4 | -3.4 | -3.4 |
| Tax Rate, % | -27.65 | -27.65 | -27.65 | -27.65 | -27.65 | -27.65 | -27.65 | -27.65 | -27.65 | -27.65 |
| EBITAT | -3,306.3 | 1,951.3 | -1,675.1 | 373.6 | -386.8 | -454.5 | -454.4 | -454.2 | -454.1 | -454.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -9,555.3 | 3,286.3 | 103.9 | 1,815.6 | 79.2 | -1,890.8 | 101.2 | 101.2 | 101.2 | 101.2 |
| WACC, % | 6.22 | 5.48 | 5.85 | 6.2 | 6.48 | 6.04 | 6.04 | 6.04 | 6.04 | 6.04 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,452.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 103 | |||||||||
| Terminal Value | 2,551 | |||||||||
| Present Terminal Value | 1,902 | |||||||||
| Enterprise Value | 449 | |||||||||
| Net Debt | 14,779 | |||||||||
| Equity Value | -14,330 | |||||||||
| Diluted Shares Outstanding, MM | 1,131 | |||||||||
| Equity Value Per Share | -12.67 |
What You Will Get
- Real Teva Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Teva’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical performance and future forecasts for Teva Pharmaceutical Industries Limited (TEVA).
- Adjustable Forecast Parameters: Modify yellow-highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Enjoy automatic updates to DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Utilize clear charts and summaries to easily interpret your valuation outcomes.
- Designed for All Levels: A straightforward, intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the pre-configured Excel file containing Teva Pharmaceutical Industries Limited's (TEVA) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment choices.
Why Choose This Calculator for Teva Pharmaceutical Industries Limited (TEVA)?
- Accurate Data: Real Teva financials ensure dependable valuation outcomes.
- Customizable: Modify key metrics such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-built calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Intuitive design and step-by-step guidance make it accessible for all users.
Who Should Use Teva Pharmaceutical Industries Limited (TEVA)?
- Investors: Gain insights and make informed decisions with a reliable evaluation of Teva's market position.
- Financial Analysts: Utilize comprehensive financial data to streamline your analysis of Teva's performance.
- Consultants: Tailor your presentations or reports efficiently with Teva's industry-specific information.
- Pharmaceutical Professionals: Enhance your knowledge of the pharmaceutical sector by studying Teva's strategies and operations.
- Educators and Students: Leverage real-world case studies of Teva in academic discussions and projects.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Teva Pharmaceutical historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Teva Pharmaceutical Industries Limited (TEVA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.